The PEARRL project officially started on May 1st and will be running for the next three years. The objectives of the PEARRL research programme are to deliver novel bio-enabling formulations and new biopharmaceutics tools to predict their in vivo performance as a means to improve efficiency and cost-competitiveness in drug development, thus facilitating earlier access of patients to “breakthrough therapies”.
-
PEARRL Project
- Beneficiaries
- Partner Organisation
-
People
>
- Supervisors >
-
Researchers
>
- Niklas Köhl (ESR1)
- Felix Ditzinger (ESR 2)
- Daniel Price (ESR 3)
- Georgia Tsakiridou (ESR 4)
- Sandra Jankovic (ESR 5)
- Chara Litou (ESR 6)
- Christina Pentafragka (ESR 7)
- Rafael Leal Monteiro Paraiso (ESR 8)
- Laura Henze (ESR 9)
- Patrick O'Dwyer (ESR 10)
- Marina Statelova (ESR 11)
- Mariana Guimarães (ESR 12)
- Ioannis Loisios-Konstantinidis (ESR 13)
- Alexandra-Roxana Ilie (ESR 14)
- Angela Effinger (ESR 15)
- Scientific Advisory Board >
- PEARRL Wiki >
- Research
- Training
- News
- Events & Meetings
-
PEARRL Project
- Beneficiaries
- Partner Organisation
-
People
>
- Supervisors >
-
Researchers
>
- Niklas Köhl (ESR1)
- Felix Ditzinger (ESR 2)
- Daniel Price (ESR 3)
- Georgia Tsakiridou (ESR 4)
- Sandra Jankovic (ESR 5)
- Chara Litou (ESR 6)
- Christina Pentafragka (ESR 7)
- Rafael Leal Monteiro Paraiso (ESR 8)
- Laura Henze (ESR 9)
- Patrick O'Dwyer (ESR 10)
- Marina Statelova (ESR 11)
- Mariana Guimarães (ESR 12)
- Ioannis Loisios-Konstantinidis (ESR 13)
- Alexandra-Roxana Ilie (ESR 14)
- Angela Effinger (ESR 15)
- Scientific Advisory Board >
- PEARRL Wiki >
- Research
- Training
- News
- Events & Meetings
RSS Feed
